Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1117-1122

  Sanders, Rogier W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

DNA prime; envelope glycoprotein; gp140 trimer; HIV 1 vaccine; subunit protein

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SAFETY; HUMAN; PRIORITY JOURNAL;

EID: 80052059030     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.97     Document Type: Article

References (22)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009)
2. Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis. 203(8), 1165-1173 (2011)
3. Gilbert P, Wang M, Wrin T, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202(4), 595-605 (2010)
4. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75(3), 1165-1171 (2001) (Pubitemid 32094675)
5. Beddows S, Schuelke N, Kirschner M, et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79(14), 8812-8827 (2005) (Pubitemid 40934792)
6. Beddows S, Franti M, Dey AK, et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360(2), 329-340 (2007) (Pubitemid 46482615)
7. Kang YK, Andjelic S, Binley JM, et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27(37), 5120-5132 (2009)
8. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75(12), 5526-5540 (2001) (Pubitemid 32488146)
9. Srivastava IK, VanDorsten K, Vojtech L, et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77(4), 2310-2320 (2003) (Pubitemid 36222754)
10. Buckner C, Gines LG, Saunders CJ, et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320(1), 167-180 (2004) (Pubitemid 38296723)
11. Derby NR, Kraft Z, Kan E, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80(17), 8745-8762 (2006) (Pubitemid 44384884)
12. Xu R, Srivastava IK, Kuller L, et al. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349(2), 276-289 (2006) (Pubitemid 43782874)
13. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382(2), 217-225 (2008)
14. Hurwitz JL, Lockey TD, Jones B, et al. First Phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants. AIDS 22(1), 149-151 (2008) (Pubitemid 350294890)
15. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3), 233-236 (2004) (Pubitemid 38332116)
16. Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68(5), 3015-3026 (1994) (Pubitemid 24129751)
17. Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization- resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 16(10), 981-994 (2000) (Pubitemid 30436497)
18. Sanders RW, Vesanen M, Schuelke N, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76(17), 8875-8889 (2002) (Pubitemid 34864082)
19. Binley JM, Sanders RW, Clas B, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74(2), 627-643 (2000) (Pubitemid 30036198)
20. Si Z, Phan N, Kiprilov E, et al. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res. Hum. Retroviruses 19(3), 217-226 (2003) (Pubitemid 36359887)
21. Pancera M, Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332(1), 145-156 (2005) (Pubitemid 40127236)
22. Dey AK, David KB, Lu M, et al. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385(1), 275-281 (2009)